- Open Access
Contribution of cysteine residues in the extracellular domain of the F protein of human respiratory syncytial virus to its function
© Day et al; licensee BioMed Central Ltd. 2006
- Received: 01 November 2005
- Accepted: 24 May 2006
- Published: 24 May 2006
The mature F protein of all known isolates of human respiratory syncytial virus (HRSV) contains fifteen absolutely conserved cysteine (C) residues that are highly conserved among the F proteins of other pneumoviruses as well as the paramyxoviruses. To explore the contribution of the cysteines in the extracellular domain to the fusion activity of HRSV F protein, each cysteine was changed to serine. Mutation of cysteines 37, 313, 322, 333, 343, 358, 367, 393, 416, and 439 abolished or greatly reduced cell surface expression suggesting these residues are critical for proper protein folding and transport to the cell surface. As expected, the fusion activity of these mutations was greatly reduced or abolished. Mutation of cysteine residues 212, 382, and 422 had little to no effect upon cell surface expression or fusion activity at 32°C, 37°C, or 39.5°C. Mutation of C37 and C69 in the F2 subunit either abolished or reduced cell surface expression by 75% respectively. None of the mutations displayed a temperature sensitive phenotype.
- Cysteine Residue
- Newcastle Disease Virus
- Cell Surface Expression
- Sendai Virus
To determine the contribution of the individual cysteine residues in the extracellular domain (ECD) to its functions, a panel of mutations in which each cysteine residue in the ECD of the HRSV F protein (residues 37, 69, 212, 313, 322, 333, 343, 358, 367, 382, 393, 416, 422, 439) was individually changed to a serine, and the effect of these mutations upon the function of the HRSV F protein was determined.
Summary of results for HRSV F cysteine mutants. Processing is defined as relative amounts of F0, F1, and F2, and is described as being equivalent to wild-type HRSV F protein (complete) or reduced. Cell surface and total expression were measured by ELISA under permeabilizing (total F protein) or non-permeabilizing (cell surface F protein) conditions using palivizumab as described in methods and reported as percent relative to wild-type HRSV F protein. Reactivity with neutralizing mAbs (palivizumab, Mab19, 47F, and 101F) as determined by flow cytometry is shown and reported as percent relative to wild-type HRSV F protein. Cell fusion activity is reported as luciferase activity measured at 32°C, 37°C, and 39.5°C as described in . All values are expressed as % relative to wild-type at the respective temperatures.
Cell surface expression (Flow cytometry)
Cell fusion (% of WT)
Cell surface protein (Non-permeabilized)
Total protein (permeabilized)
To extend these results, the effect of the cysteine mutations upon the level of cell surface expression was examined by flow cytometry using four different antibodies, 47F , 101F (a monoclonal which recognizes the site IV, V, VI region), palivizumab  or mAb19  directed against one of two major antigenic sites (II or IV, V, VI) in the F protein. Consistent with results obtained using ELISA under non-permeabilizing conditions, flow cytometry analysis demonstrated that mutation of cysteine residues 37, 313, 322, 333, 343, 358, 367, 393, 416, and 439 reduced binding of all four antibodies, while mutation of cysteine mutants C382S, and C422S retained similar levels of antibody binding as the wild-type F protein (Table 1). As the same set of cysteine mutations that reduced or abolished F0 protein cleavage and cell surface expression, also reduced or abolished cell surface binding of the four mAbs tested here, we conclude that cysteine residues 37, 313, 322, 333, 343, 358, 367, 393, 416, and 439 play a key role in the proper folding, processing, and cell surface transport of the HRSV F protein. Again, as the epitopes of these antibodies are directed against two different antigenic regions of F protein and have been shown to be largely non-conformational [43, 45], we suggest that it is unlikely that the inability to detect these cysteine mutation F proteins on the cell surface is attributable to protein misfolding which would simultaneously block the epitopes recognized by these four different antibodies, but rather reflects a true defect in cell surface transport caused by these mutations. Interestingly, mutation of residue C212, which had wild-type levels of protein expression as determined by ELISA, appeared to have somewhat reduced levels of cell surface protein (37–47% of wild-type) as determined by flow cytometry. Although the exact reason for this is not clear, it could reflect a sensitivity of this particular mutant (folding, reactivity to fixation agent, etc.) to the differences in the experimental conditions used for ELISA and flow cytometry.
Limited direct structure-function data exists for the HRSV F protein. This study utilizes a genetic approach to analyze the contribution of the individual cysteine residues in the extracellular domain in protein expression and cell fusion of the HRSV F protein and represents the first analysis of the contribution of the cysteine residues of the HRSV F protein ECD to its function. Generally, cysteine residues are critical for folding and provide structural stability to a protein via the formation of disulfide bonds. Mutation of cysteine residues 37, 313, 322, 333, 343, 358, 367, 393, 416, and 439 abolished or reduced cell surface expression to less than 7% of wild type HRSV F protein. This suggests that these residues play a key role in the proper folding and subsequent transport through the Golgi to the cell surface. Identification of the stages at which these specific cysteine mutations block the folding, maturation, and transport of the HRSV F protein is currently ongoing. Mutation of cysteine residues can often lead to a temperature sensitive (ts) phenotype such as that observed for the herpes simplex type 1 gD glycoprotein . The lack of an observable ts phenotype in this study is supported by the high thermostability of the HRSV F protein among paramyxoviruses .
From direct mapping of disulfide bonds in Sendai virus , and based upon the positional conservation of the cysteine 69 residue in the HRSV F proteins with that of Sendai virus F protein and the F proteins from other of the Paramyxoviridae, it is likely that cysteine residues 69 and 212 participate in the disulfide linkage between the F1 and F2 subunits. The Pneumovirinae members have a positionally conserved second cysteine residue in the F2 subunit (corresponds to residue 37 in HRSV F protein) (Figure 2) not found in the other Paramyxovirinae. In the model of the HRSV F ECD, this cysteine residue is predicted to make a disulfide bond with cysteine residue 439, which is also only conserved in the F proteins of the Pneumovirinae members and not found in the F proteins of the other Paramyxovirinae members. This would suggest that two disulfide bonds are formed between the F1 and F2 subunits. We are currently performing direct biochemical mapping of the disulfide linkages to formally demonstrate this. This could explain, in part, the unique thermostability described for the HRSV F protein ECD .
HRSV is a significant human pathogen, and the F protein has been identified as the target of multiple neutralizing antibodies [47, 52, 53] as well as small molecule inhibitors [54–58]. As such, the HRSV F protein represents a critical viral target for the development of new and improved preventions and treatments for HRSV induced disease. A greater understanding of its structure-function relationships would greatly facilitate the development of these new agents. The results of this study provide further support that the highly conserved HRSV F protein cysteine residues play a critical role in the structure and function of this protein. As disulfide bonds have been shown to play roles beyond proper protein folding and stabilization of protein structure , it is tempting to speculate that, similar to HIV , the disulfide bonds of the Pneumovirus F proteins may have a direct role in fusion. Our modeling and analysis suggest the presence of two disulfide bonds which join the F1 and F2 subunits of the HRSV F protein. If formally demonstrated, this would highlight a distinct structural feature of the F proteins of the Pneumovirinae not described for the F proteins of the Paramyxovirinae.
Cells, plasmids and transfections
293T cells were grown at 37°C in a humidified atmosphere of 5% CO2 and maintained in Dulbecco's modified Eagle media (DMEM) with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose and 10% FBS. Cells were tested and confirmed to be free of mycoplasma contamination. Plasmid pHRSVFoptA2, which expresses the HRSV F protein of the A2 strain whose sequence was codon optimized and derived from a known infectious HRSV cDNA , has been previously described  and served as the template for the generation of the panel of cysteine mutations by site directed mutagenesis using the QuikChange® Site-Directed Mutagenesis kit (Stratagene®, La Jolla, CA). Cells were transiently transfected using FuGENE 6 reagent (Roche Applied Science, IN) as previously described .
Metabolic labeling and immunoprecipitation
[35S]-methionine/cysteine radiolabeled cell lysates were prepared and immunoprecipitated with a cocktail of four anti-HRSV F mAbs (palivizumab, 47F, Mab19, and 101F) directed against the two major antigenic sites II and IV, V, VI  as previously described .
The binding of neutralizing monoclonal antibodies (mAbs) to HRSV F protein was assayed by ELISA using 293T cells transiently transfected with plasmids expressing either wild-type F protein, the panel of cysteine mutants, or a vector only control. 293T cells (2.0 × 104 cells/well) were plated the day before transfection in 96-well plates in DMEM, supplemented with 1.5 gms./liter sodium bicarbonate and 10% FBS. A total of 50 ngs of plasmid DNA was complexed with 0.15 μl of FuGENE 6 reagent and incubated 20 minutes room temperature in OptiMEM reduced-serum medium prior to addition to cells in serum containing medium. At 20–24 hours post-transfection, cells were assayed for binding of palivizumab under permeabilizing or non-permeabilizing conditions. Cells were fixed by the addition of 0.05% glutaraldehyde (Sigma) in 1X PBS for 15 minutes at room temperature. Cells were then either washed under conditions which permeabilizing (0.1% Triton-X100 in PBS) or non- permeabilizing (0.05% Tween-20 in PBS) conditions. These conditions were verified using an anti-RSV N protein mAb (clone # M291207, Fitzgerald Industries International, Concord, MA) and HRSV infected cells. HRSV N protein is only produced within the cytoplasm of HRSV infected cells. The anti-N mAb yields a strong positive signal on infected cells when the wash buffer containing 0.1% Triton-X100 is used, but not when wash buffer containing 0.05% Tween 20 is used (data not shown). Cells were blocked for one hour with SuperblockTM (Pierce Biotechnology, Inc., Rockford, IL) followed by incubation with either 1 μg/ml chimeric 101F IgG, 1 μg/ml palivizumab or a 1:600 dilution of mAb19 hybridoma supernatant for one hour at room temperature. Samples were then incubated with an anti-human IgG-HRP or an anti-mouse IgG-HRP as appropriate (Amersham Biosciences, Inc.) at 1:800 for one hour at room temperature followed by detection with TMB substrate (Sigma, Inc.). The reaction was stopped with the addition of 2N sulfuric acid, and the optical density at 450 nm was read. Values were calculated as percents relative to wild-type HRSV F after adjusting for background signal from the vector only control.
To confirm cell surface expression, 293T cells were transfected with plasmids expressing either wild-type F protein, the panel of cysteine mutants or a vector only control in either 6-well or 96-well formats as described above. Cells were fixed with 2% paraformaldehyde in PBS for 15 minutes at 4°C. Cells were washed with PBS containing 2% FBS and then stained with either a chimerized human version of 101F (murine V region grafted onto human IgG1κ framework) or palivizumab (IgG1κ) at 1 μg/ml with an anti-human IgG-Alexa-Fluor-488 conjugated secondary (Molecular Probes, Eugene, OR) for analysis with the FACSCalibur (BD Bisociences) and determining the mean fluorescence intensity. Data analysis was performed with Cell Quest and FloJo Analysis Software. Values were calculated as percents relative to wild-type HRSV F after adjusting for background signal from the vector only control.
Cell fusion assays
Cell fusion assays were conducted as previously described . Briefly, one population of 293T cells was co-transfected with pHRSVFOptA2 and pBD-NFκB (effectors cells), and another population of 293T cells was transfected with the pFR-Luc luciferase reporter plasmid (reporter cells). At 24 hours post transfection, effector cells were mixed with an equal amount of reporter cells in a 96-well plate and incubated an additional 24 hours prior to measurement of luciferase activity using the Steady Glo Luciferase reporter system (Promega, Inc.).
The molecular structure of HRSV F protein ECD was modeled using the human parainfluenza virus 3 virus F protein ECD structure as template [pdb code 1ztm], essentially in the same way as previously described  with a small adjustment of the residues between 331 and 346, thus allowing all pairs of cysteine residues to be positioned close enough to form disulfide bonds. Sequence alignment was carried out in ICM (Molsoft, CA) and manually adjusted. The monomer molecular model was first generated in ICM and then the trimer was assembled.
Sequence alignment was performed using the CLUSTAL W method in MegAlign program (version 5.05) from DNASTAR, Inc. (Madison, WI). Genbank accession numbers for the sequences of the viral F proteins used for the alignment are: HRSV , BRSV (NC_001989), PVM (AY729016), HMPV (NC_004148), APV (AY590688), hPIV3 (NC_001796), Sendai virus (NC_001552), Mumps virus (NC_002200), NDV (AF309418), Simian parainfluenza virus 5 (SV5) (NC_006430), Measles virus (P69353), Rinderpest virus (NC_006296), Nipah virus (NC_002728), Hendra virus (NC_001906).
We thank Geraldine Taylor for generously providing mAb19 hybridoma supernatant as well as helpful discussions and comments. We thank William Glass, Jarrat Jordan, and Lamine Mbow for critical review of this manuscript.
- Han LL, Alexander JP, Anderson LJ: Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis 1999, 179: 25-30. 10.1086/314567View ArticlePubMedGoogle Scholar
- Ison MG, Hayden FG: Viral infections in immunocompromised patients: what's new with respiratory viruses? Curr Opin Infect Dis 2002, 15: 355-367.View ArticlePubMedGoogle Scholar
- Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289: 179-186. 10.1001/jama.289.2.179View ArticlePubMedGoogle Scholar
- Whimbey E, Ghosh S: Respiratory syncytial virus infections in immunocompromised adults. Curr Clin Top Infect Dis 2000, 20: 232-255.PubMedGoogle Scholar
- Collins PL, Chanock RM, Murphy BR: Respiratory syncytial virus. In Fields Virology. Volume 1. Fourth edition. Edited by: Knipe DM and Howley PM. Philadelphia, Lippincott, Williams, and Wilkins; 2001:1443-1485.Google Scholar
- Huang YT, Collins PL, Wertz GW: Characterization of the 10 proteins of human respiratory syncytial virus: identification of a fourth envelope-associated protein. Virus Res 1985, 2: 157-173. 10.1016/0168-1702(85)90246-1View ArticlePubMedGoogle Scholar
- Bukreyev A, Whitehead SS, Murphy BR, Collins PL: Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J Virol 1997, 71: 8973-8982.PubMed CentralPubMedGoogle Scholar
- Jin H, Zhou H, Cheng X, Tang R, Munoz M, Nguyen N: Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo. Virology 2000, 273: 210-218. 10.1006/viro.2000.0393View ArticlePubMedGoogle Scholar
- Karron RA, Buonagurio DA, Georgiu AF, Whitehead SS, Adamus JE, Clements-Mann ML, Harris DO, Randolph VB, Udem SA, Murphy BR, Sidhu MS: Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci U S A 1997, 94: 13961-13966. 10.1073/pnas.94.25.13961PubMed CentralView ArticlePubMedGoogle Scholar
- Techaarpornkul S, Collins PL, Peeples ME: Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. Virology 2002, 294: 296-304. 10.1006/viro.2001.1340View ArticlePubMedGoogle Scholar
- Techaarpornkul S, Barretto N, Peeples ME: Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J Virol 2001, 75: 6825-6834. 10.1128/JVI.75.15.6825-6834.2001PubMed CentralView ArticlePubMedGoogle Scholar
- Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 2001, 289: 283-296. 10.1006/viro.2001.1138View ArticlePubMedGoogle Scholar
- Whitehead SS, Bukreyev A, Teng MN, Firestone CY, St Claire M, Elkins WR, Collins PL, Murphy BR: Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol 1999, 73: 3438-3442.PubMed CentralPubMedGoogle Scholar
- Heminway BR, Yu Y, Tanaka Y, Perrine KG, Gustafson E, Bernstein JM, Galinski MS: Analysis of respiratory syncytial virus F, G, and SH proteins in cell fusion. Virology 1994, 200: 801-805. 10.1006/viro.1994.1245View ArticlePubMedGoogle Scholar
- Teng MN, Collins PL: Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles. J Virol 1998, 72: 5707-5716.PubMed CentralPubMedGoogle Scholar
- Walsh EE, Hruska J: Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J Virol 1983, 47: 171-177.PubMed CentralPubMedGoogle Scholar
- Anderson K, Stott EJ, Wertz GW: Intracellular processing of the human respiratory syncytial virus fusion glycoprotein: amino acid substitutions affecting folding, transport and cleavage. J Gen Virol 1992, 73 ( Pt 5): 1177-1188.View ArticleGoogle Scholar
- Bolt G, Pedersen LO, Birkeslund HH: Cleavage of the respiratory syncytial virus fusion protein is required for its surface expression: role of furin. Virus Res 2000, 68: 25-33. 10.1016/S0168-1702(00)00149-0View ArticlePubMedGoogle Scholar
- Collins PL, Mottet G: Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol 1991, 72 ( Pt 12): 3095-3101.View ArticleGoogle Scholar
- Rixon HW, Brown C, Brown G, Sugrue RJ: Multiple glycosylated forms of the respiratory syncytial virus fusion protein are expressed in virus-infected cells. J Gen Virol 2002, 83: 61-66.View ArticlePubMedGoogle Scholar
- Sugrue RJ, Brown C, Brown G, Aitken J, Mc LRHW: Furin cleavage of the respiratory syncytial virus fusion protein is not a requirement for its transport to the surface of virus-infected cells. J Gen Virol 2001, 82: 1375-1386.View ArticlePubMedGoogle Scholar
- Elango N, Satake M, Coligan JE, Norrby E, Camargo E, Venkatesan S: Respiratory syncytial virus fusion glycoprotein: nucleotide sequence of mRNA, identification of cleavage activation site and amino acid sequence of N-terminus of F1 subunit. Nucleic Acids Res 1985, 13: 1559-1574.PubMed CentralView ArticlePubMedGoogle Scholar
- Zimmer G, Trotz I, Herrler G: N-glycans of F protein differentially affect fusion activity of human respiratory syncytial virus. J Virol 2001, 75: 4744-4751. 10.1128/JVI.75.10.4744-4751.2001PubMed CentralView ArticlePubMedGoogle Scholar
- Gonzalez-Reyes L, Ruiz-Arguello MB, Garcia-Barreno B, Calder L, Lopez JA, Albar JP, Skehel JJ, Wiley DC, Melero JA: Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci U S A 2001, 98: 9859-9864. 10.1073/pnas.151098198PubMed CentralView ArticlePubMedGoogle Scholar
- Gruber C, Levine S: Respiratory syncytial virus polypeptides. III. The envelope-associated proteins. J Gen Virol 1983, 64 (Pt 4): 825-832.View ArticleGoogle Scholar
- Scheid A, Choppin RW: Two disulfide-linked polypeptide chains constitute the active F protein of paramyxoviruses. Virology 1977, 80: 54-66. 10.1016/0042-6822(77)90380-4View ArticlePubMedGoogle Scholar
- Ruiz-Arguello MB, Martin D, Wharton SA, Calder LJ, Martin SR, Cano O, Calero M, Garcia-Barreno B, Skehel JJ, Melero JA: Thermostability of the human respiratory syncytial virus fusion protein before and after activation: implications for the membrane-fusion mechanism. J Gen Virol 2004, 85: 3677-3687. 10.1099/vir.0.80318-0View ArticlePubMedGoogle Scholar
- Colman PM, Lawrence MC: The structural biology of type I viral membrane fusion. Nature Rev 2003, 4: 309-319. 10.1038/nrm1076View ArticleGoogle Scholar
- Lawless-Delmedico MK, Sista P, Sen R, Moore NC, Antczak JB, White JM, Greene RJ, Leanza KC, Matthews TJ, Lambert DM: Heptad-repeat regions of respiratory syncytial virus F1 protein form a six-membered coiled-coil complex. Biochemistry 2000, 39: 11684-11695. 10.1021/bi000471yView ArticlePubMedGoogle Scholar
- Matthews JM, Young TF, Tucker SP, Mackay JP: The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil. J Virol 2000, 74: 5911-5920. 10.1128/JVI.74.13.5911-5920.2000PubMed CentralView ArticlePubMedGoogle Scholar
- Zhao X, Singh M, Malashkevich VN, Kim PS: Structural characterization of the human respiratory syncytial virus fusion protein core. Proc Natl Acad Sci U S A 2000, 97: 14172-14177. 10.1073/pnas.260499197PubMed CentralView ArticlePubMedGoogle Scholar
- Calder LJ, Gonzalez-Reyes L, Garcia-Barreno B, Wharton SA, Skehel JJ, Wiley DC, Melero JA: Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology 2000, 271: 122-131. 10.1006/viro.2000.0279View ArticlePubMedGoogle Scholar
- Chen L, Colman PM, Cosgrove LJ, Lawrence MC, Lawrence LJ, Tulloch PA, Gorman JJ: Cloning, expression, and crystallization of the fusion protein of Newcastle disease virus. Virology 2001, 290: 290-299. 10.1006/viro.2001.1172View ArticlePubMedGoogle Scholar
- Chen L, Gorman J, McKimm-Breschkin J, Lawrence L, Tulloch P, Smith B, Colman P, Lawrence M: The Structure of the Fusion Glycoprotein of Newcastle Disease Virus Suggests a Novel Paradigm for the Molecular Mechanism of Membrane Fusion. Structure 2001, 9: 255-266. 10.1016/S0969-2126(01)00581-0View ArticlePubMedGoogle Scholar
- Morton CJ, Cameron R, Lawrence LJ, Lin B, Lowe M, Luttick A, Mason A, McKimm-Breschkin J, Parker MW, Ryan J, Smout M, Sullivan J, Tucker SP, Young PR: Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay. Virology 2003, 311: 275-288. 10.1016/S0042-6822(03)00115-6View ArticlePubMedGoogle Scholar
- Smith BJ, Lawrence MC, Colman PM: Modelling the structure of the fusion protein from human respiratory syncytial virus. Protein Eng 2002, 15: 365-371. 10.1093/protein/15.5.365View ArticlePubMedGoogle Scholar
- Yin HS, Paterson RG, Wen X, Lamb RA, Jardetzky TS: Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein. Proc Natl Acad Sci U S A 2005, 102: 9288-9293. 10.1073/pnas.0503989102PubMed CentralView ArticlePubMedGoogle Scholar
- van den Hoogen BG, Bestebroer TM, Osterhaus AD, Fouchier RA: Analysis of the genomic sequence of a human metapneumovirus. Virology 2002, 295: 119-132. 10.1006/viro.2001.1355View ArticlePubMedGoogle Scholar
- Iwata S, Schmidt AC, Titani K, Suzuki M, Kido H, Gotoh B, Hamaguchi M, Nagai Y: Assignment of disulfide bridges in the fusion glycoprotein of Sendai virus. J Virol 1994, 68: 3200-3206.PubMed CentralPubMedGoogle Scholar
- McGinnes LW, Morrison TG: Nucleotide sequence of the gene encoding the Newcastle disease virus fusion protein and comparisons of paramyxovirus fusion protein sequences. Virus Res 1986, 5: 343-356. 10.1016/0168-1702(86)90028-6View ArticlePubMedGoogle Scholar
- Arumugham RG, Seid RCJ, Doyle S, Hildreth SW, Paradiso PR: Fatty acid acylation of the fusion glycoprotein of human respiratory syncytial virus. J Biol Chem 1989, 264: 10339-10342.PubMedGoogle Scholar
- Branigan PJ, Day ND, Liu C, Gutshall LL, Melero JA, Sarisky RT, Del Vecchio AM: The cytoplasmic domain of the F protein of human respiratory syncytial virus is not required for cell fusion. J General Virology 2006, 87: 395-398. 10.1099/vir.0.81481-0View ArticleGoogle Scholar
- Arbiza J, Taylor G, Lopez JA, Furze J, Wyld S, Whyte P, Stott EJ, Wertz G, Sullender W, Trudel M, et al.: Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol 1992, 73 ( Pt 9): 2225-2234.View ArticleGoogle Scholar
- Branigan PJ, Liu C, Day ND, Gutshall LL, Sarisky RT, Del Vecchio AM: Use of a novel cell-based fusion reporter assay to explore the host range of human respiratory syncytial virus F protein. Virol J 2005, 2: 54. 10.1186/1743-422X-2-54PubMed CentralView ArticlePubMedGoogle Scholar
- Toiron C, Lopez JA, Rivas G, Andreu D, Melero JA, Bruix M: Conformational studies of a short linear peptide corresponding to a major conserved neutralizing epitope of human respiratory syncytial virus fusion glycoprotein. Biopolymers 1996, 39: 537-548. PublisherFullText 10.1002/(SICI)1097-0282(199610)39:4537::AID-BIP63.0.CO;2-YView ArticlePubMedGoogle Scholar
- Garcia-Barreno B, Palomo C, Penas C, Delgado T, Perez-Brena P, Melero JA: Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J Virol 1989, 63: 925-932.PubMed CentralPubMedGoogle Scholar
- Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF: Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997, 176: 1215-1224.View ArticlePubMedGoogle Scholar
- Taylor G, Stott EJ, Furze J, Ford J, Sopp P: Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies. J Gen Virol 1992, 73 ( Pt 9): 2217-2223.View ArticleGoogle Scholar
- Long D, Cohen GH, Muggeridge MI, Eisenberg RJ: Cysteine mutants of herpes simplex virus type 1glycoprotein D exhibit temperature-sensitive properties in structure and function. J Virol 1990, 64: 5542-5552.PubMed CentralPubMedGoogle Scholar
- Gharpure MA, Wright PF, Chanock RM: Temperature-sensitive mutants of respiratory syncytial virus. J Virol 1969, 3: 414-421.PubMed CentralPubMedGoogle Scholar
- Hsu KH, Crowe JEJ, Lubeck MD, Davis AR, Hung PP, Chanock RM, Murphy BR: Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus. Vaccine 1995, 13: 509-515. 10.1016/0264-410X(94)00002-5View ArticlePubMedGoogle Scholar
- Crowe JEJ, Gilmour PS, Murphy BR, Chanock RM, Duan L, Pomerantz RJ, Pilkington GR: Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo. J Infect Dis 1998, 177: 1073-1076.View ArticlePubMedGoogle Scholar
- Johnson S, Griego SD, Pfarr DS, Doyle ML, Woods R, Carlin D, Prince GA, Koenig S, Young JF, Dillon SB: A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J Infect Dis 1999, 180: 35-40. 10.1086/314846View ArticlePubMedGoogle Scholar
- Andries K, Moeremans M, Gevers T, Willebrords R, Sommen C, Lacrampe J, Janssens F, Wyde PR: Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res 2003, 60: 209-219. 10.1016/j.antiviral.2003.07.004View ArticlePubMedGoogle Scholar
- Cianci C, Yu KL, Combrink K, Sin N, Pearce B, Wang A, Civiello R, Voss S, Luo G, Kadow K, Genovesi EV, Venables B, Gulgeze H, Trehan A, James J, Lamb L, Medina I, Roach J, Yang Z, Zadjura L, Colonno R, Clark J, Meanwell N, Krystal M: Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother 2004, 48: 413-422. 10.1128/AAC.48.2.413-422.2004PubMed CentralView ArticlePubMedGoogle Scholar
- Douglas JL, Panis ML, Ho E, Lin KY, Krawczyk SH, Grant DM, Cai R, Swaminathan S, Cihlar T: Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J Virol 2003, 77: 5054-5064. 10.1128/JVI.77.9.5054-5064.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Razinkov V, Gazumyan A, Nikitenko A, Ellestad G, Krishnamurthy G: RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem Biol 2001, 8: 645-659. 10.1016/S1074-5521(01)00042-4View ArticlePubMedGoogle Scholar
- Sudo K, Konno K, Watanabe W, Shigeta S, Yokota T: Mechanism of selective inhibition of respiratory syncytial virus by a benzodithiin compound (RD3-0028). Microbiol Immunol 2001, 45: 531-537.View ArticlePubMedGoogle Scholar
- Hogg PJ: Disulfide bonds as switches for protein function. Trends Biochem Sci 2003, 28: 210-214. 10.1016/S0968-0004(03)00057-4View ArticlePubMedGoogle Scholar
- Barbouche R, Miquelis R, Jones IM, Fenouillet E: Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion. J Biol Chem 2003, 278: 3131-3136. 10.1074/jbc.M205467200View ArticlePubMedGoogle Scholar
- Collins PL, Hill MG, Camargo E, Grosfeld H, Chanock RM, Murphy BR: Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A 1995, 92: 11563-11567. 10.1073/pnas.92.25.11563PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.